Key Highlights
- Biogen has entered into a multi-target partnership with Alloy Therapeutics to leverage the AntiClastic™ ASO platform for developing antisense therapeutics.
- Financial terms include upfront compensation to Alloy, with additional milestone-based payments and royalty structures tied to commercialization.
- The partnership between Biogen and Alloy dates back to 2020, initially concentrating on antibody-based therapies.
- RBC Capital reduced Biogen’s price target from $233 to $213 while maintaining its Outperform recommendation.
- Analyst consensus places BIIB’s average price target at $210.30 with an overweight rating.
Biogen has entered into a strategic partnership with Alloy Therapeutics, securing access to the company’s proprietary AntiClastic™ antisense oligonucleotide (ASO) technology platform for developing therapies targeting several confidential disease areas.
Under the terms of this arrangement, Alloy will collect an initial payment, with opportunities to earn additional compensation through development milestone achievements and tiered royalty payments based on future product sales.
This marks an evolution in the companies’ relationship, which began in 2020 with a focus on antibody-based treatment development. The current agreement shifts their collaboration toward the genetic medicine sector.
Biogen brings considerable experience in antisense oligonucleotide therapeutics to the partnership. The company’s Spinraza therapy for spinal muscular atrophy represents one of the most successful ASO treatments currently available. This latest agreement aims to expand upon that expertise through Alloy’s innovative platform technology.
Errik Anderson, CEO of Alloy, characterized the partnership straightforwardly: “Biogen is a leader in the space and has made huge contributions to ASO technologies. We view this as validation and an opportunity to build on their experience.”
The collaboration aims to advance three key objectives through Alloy’s platform: increased therapeutic potency, reduced immunogenicity profiles, and superior tissue-specific targeting capabilities.
Alloy’s Partnership Portfolio
Headquartered in Waltham, Massachusetts, Alloy has established a business model centered on collaborating with biopharmaceutical companies across the drug discovery and development spectrum. Since its founding in 2017, the company has executed approximately 200 partnership agreements, yielding more than 100 licensed therapeutic candidates.
The company’s platform has contributed to 22 drug candidates that have advanced to human clinical testing. In a notable 2024 transaction, Sanofi secured rights to the same ASO platform in a deal valued at up to $400 million, targeting potential therapies for central nervous system disorders.
Christian Cobaugh, who leads Alloy’s Genetic Medicine Division as CEO, indicated that the Biogen partnership will enable the company to extend its capabilities beyond initial discovery phases into later-stage development activities.
Differing from many platform-focused biotech firms that use partnerships to finance proprietary drug pipelines, Alloy has intentionally structured its business around collaboration as its primary revenue model.
Wall Street’s Perspective on Biogen
From an analyst perspective, RBC Capital revised its BIIB price objective downward to $213 from its previous $233 target on April 7, though the firm maintained its Outperform rating.
According to FactSet’s analyst survey, the consensus price target for Biogen currently sits at $210.30, accompanied by an overweight recommendation.
BIIB shares declined 2.82% on the session when the partnership was publicly disclosed.
